Molecular Epidemiology and Evolution of Coxsackievirus A9
Nineteen CVA9 isolates were obtained between 2010 and 2019 from six provinces of mainland China, using the HFMD surveillance network established in China. Nucleotide sequencing revealed that the full-length VP1 of 19 CVA9 isolates was 906 bases encoding 302 amino acids. The combination of the thresh...
| Main Authors: | , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Viruses |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4915/14/4/822 |
| _version_ | 1797434169055248384 |
|---|---|
| author | Hehe Zhao Jianxing Wang Jianhua Chen Ruifang Huang Yong Zhang Jinbo Xiao Yang Song Tianjiao Ji Qian Yang Shuangli Zhu Dongyan Wang Huanhuan Lu Zhenzhi Han Guoyan Zhang Jichen Li Dongmei Yan |
| author_facet | Hehe Zhao Jianxing Wang Jianhua Chen Ruifang Huang Yong Zhang Jinbo Xiao Yang Song Tianjiao Ji Qian Yang Shuangli Zhu Dongyan Wang Huanhuan Lu Zhenzhi Han Guoyan Zhang Jichen Li Dongmei Yan |
| author_sort | Hehe Zhao |
| collection | DOAJ |
| description | Nineteen CVA9 isolates were obtained between 2010 and 2019 from six provinces of mainland China, using the HFMD surveillance network established in China. Nucleotide sequencing revealed that the full-length VP1 of 19 CVA9 isolates was 906 bases encoding 302 amino acids. The combination of the thresholds of the phylogenetic tree and nucleotide divergence of different genotypes within the same serotype led to a value of 15–25%, and enabled CVA9 worldwide to be categorized into ten genotypes: A–J. The phylogenetic tree showed that the prototype strain was included in genotype A, and that the B, C, D, E, H, and J genotypes disappeared during virus evolution, whereas the F, I, and G genotypes showed co-circulation. Lineage G was the dominant genotype of CVA9 and included most of the strains from nine countries in Asia, North America, Oceania, and Europe. Most Chinese strains belonged to the G genotype, suggesting that the molecular epidemiology of China is consistent with that observed worldwide. The 165 partial VP1 strains (723 nt) showed a mean substitution rate of 3.27 × 10<sup>−3</sup> substitution/site/year (95% HPD range 2.93–3.6 × 10<sup>−3</sup>), dating the tMRCA of CVA9 back to approximately 1922 (1911–1932). The spatiotemporal dynamics of CVA9 showed the spread of CVA9 obviously increased in recent years. Most CVA9 isolates originated in USA, but the epidemic areas of CVA9 are now concentrated in the Asia–Pacific region, European countries, and North America. Recombination analysis within the enterovirus B specie (59 serotypes) revealed eight recombination patterns in China at present, CVB4, CVB5, E30, CVB2, E11, HEV106, HEV85, and HEV75. E14, and E6 may act as recombinant donors in multiple regions. Comparison of temperature sensitivity revealed that temperature-insensitive strains have more amino acid substitutions in the RGD motif of the VP1 region, and the sites T283S, V284M, and R288K in the VP1 region may be related to the temperature tolerance of CVA9. |
| first_indexed | 2024-03-09T10:28:21Z |
| format | Article |
| id | doaj.art-923595cee5334f8191c860a75d708339 |
| institution | Directory Open Access Journal |
| issn | 1999-4915 |
| language | English |
| last_indexed | 2024-03-09T10:28:21Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Viruses |
| spelling | doaj.art-923595cee5334f8191c860a75d7083392023-12-01T21:31:16ZengMDPI AGViruses1999-49152022-04-0114482210.3390/v14040822Molecular Epidemiology and Evolution of Coxsackievirus A9Hehe Zhao0Jianxing Wang1Jianhua Chen2Ruifang Huang3Yong Zhang4Jinbo Xiao5Yang Song6Tianjiao Ji7Qian Yang8Shuangli Zhu9Dongyan Wang10Huanhuan Lu11Zhenzhi Han12Guoyan Zhang13Jichen Li14Dongmei Yan15National Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinaDepartment for Viral Disease Control and Prevention, Shandong Center for Disease Control and Prevention, Jinan 250014, ChinaDepartment for Viral Disease Control and Prevention, Gansu Center for Disease Control and Prevention, Lanzhou 730000, ChinaDepartment for Communicable Disease Control and Prevention, Xinjiang Uygur Autonomous Region Center for Disease Control and Prevention, Urumqi 830011, ChinaNational Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinaNational Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinaNational Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinaNational Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinaNational Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinaNational Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinaNational Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinaNational Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinaNational Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinaNational Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinaNational Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinaNational Polio Laboratory, WHO WPRO Regional Polio Reference Laboratory, National Health Commission Key Laboratory for Biosecurity, National Health Commission Key Laboratory for Medical Virology, National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, ChinaNineteen CVA9 isolates were obtained between 2010 and 2019 from six provinces of mainland China, using the HFMD surveillance network established in China. Nucleotide sequencing revealed that the full-length VP1 of 19 CVA9 isolates was 906 bases encoding 302 amino acids. The combination of the thresholds of the phylogenetic tree and nucleotide divergence of different genotypes within the same serotype led to a value of 15–25%, and enabled CVA9 worldwide to be categorized into ten genotypes: A–J. The phylogenetic tree showed that the prototype strain was included in genotype A, and that the B, C, D, E, H, and J genotypes disappeared during virus evolution, whereas the F, I, and G genotypes showed co-circulation. Lineage G was the dominant genotype of CVA9 and included most of the strains from nine countries in Asia, North America, Oceania, and Europe. Most Chinese strains belonged to the G genotype, suggesting that the molecular epidemiology of China is consistent with that observed worldwide. The 165 partial VP1 strains (723 nt) showed a mean substitution rate of 3.27 × 10<sup>−3</sup> substitution/site/year (95% HPD range 2.93–3.6 × 10<sup>−3</sup>), dating the tMRCA of CVA9 back to approximately 1922 (1911–1932). The spatiotemporal dynamics of CVA9 showed the spread of CVA9 obviously increased in recent years. Most CVA9 isolates originated in USA, but the epidemic areas of CVA9 are now concentrated in the Asia–Pacific region, European countries, and North America. Recombination analysis within the enterovirus B specie (59 serotypes) revealed eight recombination patterns in China at present, CVB4, CVB5, E30, CVB2, E11, HEV106, HEV85, and HEV75. E14, and E6 may act as recombinant donors in multiple regions. Comparison of temperature sensitivity revealed that temperature-insensitive strains have more amino acid substitutions in the RGD motif of the VP1 region, and the sites T283S, V284M, and R288K in the VP1 region may be related to the temperature tolerance of CVA9.https://www.mdpi.com/1999-4915/14/4/822coxsackievirus A9genotypingrecombinationevolutionary reconstruction |
| spellingShingle | Hehe Zhao Jianxing Wang Jianhua Chen Ruifang Huang Yong Zhang Jinbo Xiao Yang Song Tianjiao Ji Qian Yang Shuangli Zhu Dongyan Wang Huanhuan Lu Zhenzhi Han Guoyan Zhang Jichen Li Dongmei Yan Molecular Epidemiology and Evolution of Coxsackievirus A9 Viruses coxsackievirus A9 genotyping recombination evolutionary reconstruction |
| title | Molecular Epidemiology and Evolution of Coxsackievirus A9 |
| title_full | Molecular Epidemiology and Evolution of Coxsackievirus A9 |
| title_fullStr | Molecular Epidemiology and Evolution of Coxsackievirus A9 |
| title_full_unstemmed | Molecular Epidemiology and Evolution of Coxsackievirus A9 |
| title_short | Molecular Epidemiology and Evolution of Coxsackievirus A9 |
| title_sort | molecular epidemiology and evolution of coxsackievirus a9 |
| topic | coxsackievirus A9 genotyping recombination evolutionary reconstruction |
| url | https://www.mdpi.com/1999-4915/14/4/822 |
| work_keys_str_mv | AT hehezhao molecularepidemiologyandevolutionofcoxsackievirusa9 AT jianxingwang molecularepidemiologyandevolutionofcoxsackievirusa9 AT jianhuachen molecularepidemiologyandevolutionofcoxsackievirusa9 AT ruifanghuang molecularepidemiologyandevolutionofcoxsackievirusa9 AT yongzhang molecularepidemiologyandevolutionofcoxsackievirusa9 AT jinboxiao molecularepidemiologyandevolutionofcoxsackievirusa9 AT yangsong molecularepidemiologyandevolutionofcoxsackievirusa9 AT tianjiaoji molecularepidemiologyandevolutionofcoxsackievirusa9 AT qianyang molecularepidemiologyandevolutionofcoxsackievirusa9 AT shuanglizhu molecularepidemiologyandevolutionofcoxsackievirusa9 AT dongyanwang molecularepidemiologyandevolutionofcoxsackievirusa9 AT huanhuanlu molecularepidemiologyandevolutionofcoxsackievirusa9 AT zhenzhihan molecularepidemiologyandevolutionofcoxsackievirusa9 AT guoyanzhang molecularepidemiologyandevolutionofcoxsackievirusa9 AT jichenli molecularepidemiologyandevolutionofcoxsackievirusa9 AT dongmeiyan molecularepidemiologyandevolutionofcoxsackievirusa9 |